- Home
- TTNP vs INM Comparison
TTNP vs INM Comparison
Compare TTNP & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTNP
- INM
- Stock Information
- Founded
- TTNP 1991
- INM 1981
- Country
- TTNP United States
- INM Canada
- Employees
- TTNP N/A
- INM N/A
- Industry
- TTNP Biotechnology: Biological Products (No Diagnostic Substances)
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- TTNP Health Care
- INM Health Care
- Exchange
- TTNP Nasdaq
- INM Nasdaq
- Market Cap
- TTNP 5.4M
- INM 4.4M
- IPO Year
- TTNP 1996
- INM N/A
- Fundamental
- Price
- TTNP $4.23
- INM $2.11
- Analyst Decision
- TTNP
- INM
- Analyst Count
- TTNP 0
- INM 0
- Target Price
- TTNP N/A
- INM N/A
- AVG Volume (30 Days)
- TTNP 92.5K
- INM 42.3K
- Earning Date
- TTNP 08-14-2025
- INM 09-29-2025
- Dividend Yield
- TTNP N/A
- INM N/A
- EPS Growth
- TTNP N/A
- INM N/A
- EPS
- TTNP N/A
- INM N/A
- Revenue
- TTNP N/A
- INM $4,920,990.00
- Revenue This Year
- TTNP N/A
- INM N/A
- Revenue Next Year
- TTNP N/A
- INM N/A
- P/E Ratio
- TTNP N/A
- INM N/A
- Revenue Growth
- TTNP N/A
- INM N/A
- 52 Week Low
- TTNP $3.03
- INM $1.72
- 52 Week High
- TTNP $6.43
- INM $8.27
- Technical
- Relative Strength Index (RSI)
- TTNP 45.73
- INM 35.28
- Support Level
- TTNP $3.58
- INM $2.22
- Resistance Level
- TTNP $4.45
- INM $2.25
- Average True Range (ATR)
- TTNP 0.37
- INM 0.08
- MACD
- TTNP -0.08
- INM 0.00
- Stochastic Oscillator
- TTNP 36.93
- INM 26.67
About TTNP Titan Pharmaceuticals Inc.
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.